TokenPost topic

VIKTORIA-1

1 TokenPost story is tagged VIKTORIA-1. The newest appear first.

Latest VIKTORIA-1 stories

• Celcuity Trial Finds 21.5-Month Progression-Free Survival in Breast Cancer Subgroup

  Patients with PIK3CA-mutated disease and no liver metastases had median progression-free survival of 21.5 months on the gedatolisib triplet, versus 9.1 months on the control regimen.

  Oct 24, 2026, 12:51 PM EDT · Business